Axsome Therapeutics, Inc.

• BE Baird Equity Asset Management Q2 2026 Commentary and Market Outlook ↗ Baird Small/Mid Cap Growth added software, AI-infrastructure industrials and commercial-stage therapeutics while exiting holdings where conviction or the original thesis had weakened. The strategy argues that data-center spending supports demand for cooling, power and infrastructure, but maintains discipline as AI-led market leadership becomes increasingly concentrated. Q2 2026 AAON $6.8BAGYS $2.8BALKS $6.9B +6

All coverage of AXSM →